Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>Jyoti Nangalia, Anthony R. Green, Elli Papaemmanuil et al.|New England Journal of Medicine|2013Cited by 1.7k
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisAyalew Tefferi, Alessandro M. Vannucchi|Blood|2014Cited by 722
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al.|Haematologica|2015Cited by 252
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al.|The Lancet|2023Cited by 181
Co‐targeting the PI3K/ <scp>mTOR</scp> and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasmsNiccolò Bartalucci, Alessandro M. Vannucchi|Journal of Cellular and Molecular Medicine|2013Cited by 136